A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms (NCT07008118)

🧪 Interventions in This Study

• INCA035784 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (26 Sites)

Showing the first 25 of 26 sites.

• Mayo Clinic Hospital — Phoenix, Arizona
• Stanford University — Palo Alto, California
• Colorado Blood Cancer Institute — Denver, Colorado
• Mayo Clinic-Florida — Jacksonville, Florida
• University of Chicago Medical Center — Chicago, Illinois
• Johns Hopkins University — Baltimore, Maryland
• Icahn School of Medicine At Mount Sinai — New York, New York
• University of North Carolina At Chapel Hill — Chapel Hill, North Carolina
• South Austin Medical Center — Austin, Texas
• University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood — Dallas, Texas
• Huntsman Cancer Institute At University of Utah — Salt Lake City, Utah
• Medical College of Wisconsin — Milwaukee, Wisconsin
• Macquarie University Hospital — Sydney, New South Wales
• Royal Adelaide Hospital — Adelaide, South Australia
• The Alfred Hospital — Melbourne, Victoria
• Linear Clinical Research — Nedlands, Western Australia
• Cliniques Universitaires Saint-Luc — Brussels,
• Universitair Ziekenhuis Gent — Ghent,
• Universitaire Ziekenhuizen Leuven — Leuven,
• Universitaetsklinikum Dresden — Dresden,
• Universitatsklinikum Halle (Saale) — Halle,
• Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii — Mainz,
• Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii — Bergamo,
• Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica — Florence,
• Fondazione Irccs Ca Granda Ospedale Maggiore — Milan,

📞 Contact the Study Coordinator

Phone: (855) 463-3463

Email: medinfo@incyte.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myeloproliferative Neoplasms

• A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms — Birmingham, Alabama
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms — Herston, Queensland
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms — Duarte, California
• Study of INCA036978 in Participants With Myeloproliferative Neoplasms — Birmingham, Alabama
• Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation — Chicago, Illinois

Explore by condition: All Myeloproliferative Neoplasms clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.